Chat with us, powered by LiveChat Publications | Page 3 Of 19 | Lhasa Limited
Lhasa Logo

Publications

Read our latest publications

Filter by:

Solution

Publications Specific Solution Area

Publication Type

Date

  1. Paper

    Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity Data

    • Feb 2026
    • Carcinogenicity assessment, Nitrosamine impurity risk assessment

  2. Paper

    Establishing Best Practice for N-Nitrosamine Read-Across and Surrogate Selection

    • Dec 2025
    • AI/PDE, Complex Nitrosamines, Nitrosamine impurity risk assessment, Safety profiling in drug discovery

  3. Paper

    Development of a Skin Sensitization Site-of-Contact Exposure Threshold (SoCET) for Botanicals and Natural Substances

    • Nov 2025
    • Skin sensitisation assessment

  4. Paper

    Evaluating the ability of defined approaches to predict the human skin sensitisation potential of chemicals previously untested in new approach methodologies

    • Nov 2025
    • Skin sensitisation assessment

  5. Paper

    Computational mechanistic study on N-nitrosation reaction of secondary amines

    • Oct 2025
    • Nitrosamine impurity risk assessment

  6. Poster

    Using an AOP framework to identify the most human-relevant test species – for confident single-species DART assessments

    • Sep 2025
    • Safety profiling in drug discovery

  7. Paper

    Nitrite testing in excipients – Industry best practices

    • Aug 2025
    • Nitrites

  8. Poster

    Can the Second Species Be Replaced by an Adverse Outcome Pathway-Based In Silico Model?

    • Aug 2025
    • Carcinogenicity assessment, Safety profiling in drug discovery

  9. Paper

    Evaluating the Lifetime Cumulative Dose as a Basis for Carcinogenic potency of Nitrosamines

    • Jul 2025
    • Carcinogenicity assessment

  10. Paper

    Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines

    • May 2025
    • Nitrosamine impurity risk assessment

  11. Paper

    HESI GTTC Ring Trial: Concordance between Ames and Rodent Carcinogenicity Outcomes for N-Nitrosamines (NAs) with Rat and Hamster Metabolic Conditions

    • May 2025
    • Carcinogenicity assessment, Nitrosamine impurity risk assessment

  12. Infographic

    How to overcome the critical challenges faced in forced degradation studies

    • Mar 2025
    • Impurity and degradant control